Advanced Search

Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2010 February;62(1) > Minerva Pediatrica 2010 February;62(1):71-8



A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532

Frequency: Bi-Monthly

ISSN 0026-4946

Online ISSN 1827-1715


Minerva Pediatrica 2010 February;62(1):71-8


Pediatric antifungal therapy. Part II: neonatal infections

Allen U., Richardson S., McGuire W., Bow E., Robinson J., Rotstein C., Doyle J., Davies D., Hui C., Le Saux N., Merchant P., Laverdiere M., Read S.

Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

language: English


top of page